Common Contracts
8 similar Agency Agreement contracts by Algernon Pharmaceuticals Inc.
AGENCY AGREEMENTAgency Agreement • June 28th, 2022
Research Capital Corporation (the “Agent”) understands that Algernon Pharmaceuticals Inc. (the “Company”) proposes to offer and sell an aggregate of up to 533,333 units of the Company (the “Initial Units”) to the public in accordance with the terms of this agency agreement (this “Agreement”). The Company hereby appoints the Agent to act as the Company’s exclusive and lead agent and sole bookrunner to offer and sell on a commercially reasonable “best efforts” agency basis the Initial Units at a price of
AGENCY AGREEMENTAgency Agreement • January 21st, 2022 • Algernon Pharmaceuticals Inc. • Pharmaceutical preparations • British Columbia
Algernon Pharmaceuticals Inc. (the "Company") hereby engages Mackie Research Capital Corporation (the "Agent") to act as its exclusive agent to offer and sell on a commercially reasonable "best efforts" agency basis a minimum of $2,500,000 of units (the "Minimum Offering") and a maximum of up to $5,000,000 of units (the "Maximum Offering") of the Company (the "Initial Units"), at an offering price of $0.11 per Initial Unit (the "Issue Price"), upon and subject to the terms and conditions contained herein (the "Offering"). Each Initial Unit shall consist of one Common Share (as defined below) (each an "Initial Share" and collectively the "Initial Shares") and one Common Share purchase warrant of the Company (each such Common Share purchase warrant being an "Initial Warrant" and collectively, the "Initial Warrants"). For greater certainty, the Minimum Offering shall consist of 27,727,272 Initial Units and the Maximum Offering shall consist of 45,454,545 Initial Units.
AGENCY AGREEMENTAgency Agreement • April 19th, 2021 • Ontario
Stem Holdings, Inc. (the “Company”) hereby engages Canaccord Genuity Corp. (the “Agent”) to act as its exclusive agent to offer and sell on a “commercially reasonable efforts” agency basis a minimum of 16,363,636 and a maximum of 17,272,728 units of the Company (the “Initial Units”), at an offering price of $0.55 per Initial Unit (the “Issue Price”), for aggregate gross proceeds of a minimum of $9,000,000 and a maximum of $9,500,000, upon and subject to the terms and conditions contained herein (the “Offering”). Each Initial Unit shall consist of one Common Share (as defined below) (each an “Initial Share” and collectively the “Initial Shares”) and one Common Share purchase warrant of the Company (each an “Initial Warrant” and collectively, the “Initial Warrants”).
AGENCY AGREEMENTAgency Agreement • December 14th, 2020
The undersigned, Stifel Nicolaus Canada Inc. (the “Agent”), as sole agent and bookrunner, on its own behalf, understands that Voyager Digital Ltd. (the “Company”) proposes to create, offer, issue and sell up to 4,666,675 special warrants of the Company (the “Initial Special Warrants”) at a price of $1.50 per Initial Special Warrant (the “Issue Price”) for aggregate gross proceeds of up to $7,000,013, or such other number of Special Warrants as the Agent and the Company may agree (together with the Agent’s Option (as defined below), the “Offering”), subject to the terms and conditions set out below. In addition, the Company has granted to the Agent an option (the “Agent’s Option”) exercisable, in whole or in part, at any time up to forty-eight (48) hours prior to the Time of Closing (as defined herein) to arrange for the sale of such number of additional special warrants of the Company as is equal to 15% of the number of Initial Special Warrants (the “Additional Special Warrants” and, t
AGENCY AGREEMENTAgency Agreement • May 13th, 2020
The undersigned, Mackie Research Capital Corporation (the “Agent”), understands that Algernon Pharmaceuticals Inc. (the “Company”) proposes to create, offer, issue and sell up to 17,143,000 special warrants of the Company (“Initial Special Warrants”), at a price of $0.35 per Special Warrant (the “Issue Price”), for aggregate gross proceeds of up to $6,000,050, or such other number of Initial Special Warrants as the Agent and the Company may agree (together with the Agent’s Option (as defined below), the “Offering”), subject to the terms and conditions set out below. In addition, the Company has granted to the Agent an option (the “Agent’s Option”) exercisable, in whole or in part, at any time up to forty- eight (48) hours prior to the Time of Closing (as defined herein) to arrange for the sale of such number of additional special warrants of the Company as is equal to up to 15% of the number of Initial Special Warrants (the “Additional Special Warrants” and, together with the Initial S
AMENDED AND RESTATED AGENCY AGREEMENTAgency Agreement • November 1st, 2019 • British Columbia
Algernon Pharmaceuticals Inc. (the “Company”) hereby engages Mackie Research Capital Corporation (the “Agent”) to act as its exclusive agent to offer and sell on a commercially reasonable “best efforts” agency basis a minimum of $2,000,000 of units (the “Minimum Offering”) and a maximum of up to
AMENDED AND RESTATED AGENCY AGREEMENTAgency Agreement • October 22nd, 2019
Algernon Pharmaceuticals Inc. (the “Company”) hereby engages Mackie Research Capital Corporation (the “Agent”) to act as its exclusive agent to offer and sell on a commercially reasonable “best efforts” agency basis a minimum of $2,000,000 of units (the “Minimum Offering”) and a maximum of up to
AGENCY AGREEMENTAgency Agreement • October 1st, 2019 • British Columbia
Algernon Pharmaceuticals Inc. (the “Company”) hereby engages Mackie Research Capital Corporation (the “Agent”) to act as its exclusive agent to offer and sell on a commercially reasonable “best efforts” agency basis a minimum of $2,500,000 of units (the “Minimum Offering”) and a maximum of up to
